Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Work In Process (2022 - 2024)

Atara Biotherapeutics filings provide 3 years of Work In Process readings, the most recent being $9.7 million for Q4 2024.

  • On a quarterly basis, Work In Process rose 31.47% to $9.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $9.7 million, a 31.47% increase, with the full-year FY2024 number at $9.7 million, up 31.47% from a year prior.
  • Work In Process hit $9.7 million in Q4 2024 for Atara Biotherapeutics, down from $12.3 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $15.1 million in Q2 2024 to a low of $372000.0 in Q4 2022.
  • Median Work In Process over the past 3 years was $7.4 million (2023), compared with a mean of $7.8 million.
  • Biggest five-year swings in Work In Process: skyrocketed 1881.45% in 2023 and later soared 31.47% in 2024.
  • Atara Biotherapeutics' Work In Process stood at $372000.0 in 2022, then skyrocketed by 1881.45% to $7.4 million in 2023, then soared by 31.47% to $9.7 million in 2024.
  • The last three reported values for Work In Process were $9.7 million (Q4 2024), $12.3 million (Q3 2024), and $15.1 million (Q2 2024) per Business Quant data.